RxDoctor Payments Data

Krystle Reed

Family · Sullivan, MONPI 1215216239

Payments from drug & device makers

$5,794in general payments, 2019–2025

Across 310 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$394
  • Lilly USA, LLC$285
  • Novartis$253
  • Astellas Pharma US Inc$227
  • Boehringer Ingelheim$204
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,69498%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,794 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$12,870
Medicare patients
69
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$71,862
MounjaroTirzepatide41$49,110
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$46,650
JardianceEmpagliflozin41$41,921
VraylarCariprazine Hcl14$27,060
EliquisApixaban26$22,846
MyrbetriqMirabegron29$20,049
Repatha SureclickEvolocumab13$16,550
AptiomEslicarbazepine Acetate12$15,964
XareltoRivaroxaban15$12,864
FarxigaDapagliflozin Propanediol12$12,785
Gabapentin82$1,433
Omeprazole94$1,274
ValacyclovirValacyclovir Hcl19$1,261
Levothyroxine Sodium182$1,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$394$71,86267 claims
Lilly USA, LLCMounjaro$285$49,11041 claims
GSKTrelegy Ellipta$72$46,65043 claims
Boehringer IngelheimJardiance$204$41,92141 claims
AbbVieVraylar$2,678$27,06014 claims
PfizerEliquis$180$22,84626 claims
Astellas Pharma US IncMyrbetriq$227$20,04929 claims
Johnson & JohnsonXarelto$64$12,86415 claims
AstraZenecaFarxiga$138$12,78512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.

Other family in Sullivan

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →